Navigation Links
Anterios, Inc. CEO And Founder, Jon Edelson, To Present At Needham & Company's 12th Annual Healthcare Conference
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today that CEO and Founder, Jon Edelson , MD will be presenting at Needham & Company's 12th Annual Healthcare Conference in New York City on April 30, 2013. Dr. Edelson will be joining a roster of presenters that includes senior management from some of the most well respected public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology, and Diagnostics sectors.

"I'm looking forward to presenting at Needham's Annual Healthcare Conference and sharing with the investment community the latest company news from Anterios," stated Dr. Edelson.  "We are at an important phase of our clinical development with ANT-1207, our topical botulinum prescription product.  ANT-1207 has true potential for expanding the aesthetic and medical dermatology marketplace."

About ANT-1207
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The Company believes that this treatment has the potential to greatly expand the market for botulinum as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.

ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. Botulinum Type A.  

ANT-1207 has been studied for the indications of lateral canthal lines (Crow's Feet wrinkles), hyperhidrosis and acne in multi-center, double-blind, randomized, controlled, dose-escalation studies enrolling approximately 250 subjects. These studies demonstrated that ANT-1207 was well tolerated and demonstrated clinically and statistically significant efficacy versus controls. The Company is currently conducting Phase 2b clinical trials on ANT-1207.

About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at www.anteriosinc.com.


'/>"/>
SOURCE Anterios, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cempra to Present Data on Solithromycins (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
5. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
6. NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
7. Lexicon To Present At The Needham Healthcare Conference
8. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
9. KaloBios to Present at Needham Healthcare Conference
10. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
11. MEI Pharma CEO To Present At Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited to announce ... Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on the face, ... ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of the body ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Pot Valet is ... service growing to every city in the state, and soon, every state in the ... their need to visit a cannabis dispensary altogether. , According to Pot ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... Seattle, WA and Lighthouse Point, FL (PRWEB) , ... ... ... Seattle-based healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology ... that examined patient care data to quantify the dollar amount of attributable savings ...
Breaking Medicine News(10 mins):